Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
PIPELINE TO PROFITS
A little more about that … Kaiser Health News infographic!
By Dr. David E. Marcinko MBA via Georgia Pharmacy Association
***
Recently, KHN ran an infographic from Kaiser Health News that gave a rough explanation of how the money flows in the sale of a brand-name drug.
After thinking about it a bit, Greg Reybold, Vice President of Public Policy & Association Counsel for the Georgia Pharmacy Association, noticed some fundamental flaws.
“The infographic helps shed light on a process that lacks fundamental transparency,” he said, “but it doesn’t reflect all of the practices engaged in by some PBMs.”
Furthermore, he added,
“There are times, unbeknownst to patients, when some PBMs charge patients copays that are significantly higher than the cost of the drugs themselves, or they steer patients to brand name drugs for which the PBM receives a rebate when there is a less costly generic available.”
He also noted the infographic:
“reflects that the pharmacy make a profit — when in fact there are many times pharmacies lose money on prescriptions they fill through low reimbursements, the imposition of different types of fees, and aggressive audits.”
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
- PRACTICES: www.BusinessofMedicalPractice.com
- HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
- CLINICS: http://www.crcpress.com/product/isbn/9781439879900
- ADVISORS: www.CertifiedMedicalPlanner.org
- FINANCE: Financial Planning for Physicians and Advisors
- INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
- Dictionary of Health Economics and Finance
- Dictionary of Health Information Technology and Security
- Dictionary of Health Insurance and Managed Care
***
Share this:
Filed under: Drugs and Pharma | Tagged: cost of Rx drugs, Greg Reybold, KAISER HEALTH NEWS., PBM, Pharmacy Benefit Mangers |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Healthcare Triage: Orphan Drugs: An Introduction Video
We at Healthcare Triage couldn’t be more excited about this month. We’re doing a whole month on orphan drugs, with the help of Nick Bagley. He wrote a lot about them, and we begged him to let us adapt his work into a series.
http://theincidentaleconomist.com/wordpress/healthcare-triage-orphan-drugs-an-introduction/
This is the Introduction. Over the next few weeks, there will be three more. Enjoy!
Aaron Carroll MD via Ann Miller RN MHA
LikeLike
90% of Employers Say Drug Prices Are Greatest Threat to Affordability
The National Alliance of Healthcare Purchaser Coalitions recently conducted a survey of employers and private purchasers. Here are some key findings on the greatest threats to healthcare affordability:
• 90% of employers say drug prices are the greatest threat to affordability of employer-provided coverage.
• Nearly 3 in 4 (73%) say lack of transparency is a threat to affordability of employer-provided coverage.
• 71% say hospital prices are a threat to affordability of employer-provided health coverage.
• Nearly 3 in 5 (58%) say surprise medical bills are a threat to affordability of coverage.
• 53% say overuse of low-value services/waste (53%) are the greatest threat to affordability of coverage.
Source: National Alliance, September 29, 2020
LikeLike
[…] Drug Middlemen: https://medicalexecutivepost.com/2022/03/14/drugs-money-and-the-middleman/ […]
LikeLike